Pareto analyst Filip Wiberg downgraded Xvivo Perfusion (XVIPF) to Hold from Buy with a price target of SEK 500, down from SEK 560. The firm says it is time for the shares to “take a breather.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.